期刊文献+

环氧合酶抑制剂在肝癌预防和治疗中的研究进展 被引量:2

Advancements of cyclooxygenase inhibitor in the prevention and treatment of hepatoma
下载PDF
导出
摘要 研究显示在许多肿瘤中,环氧合酶(COX)2及其产物过度表达.非甾体类抗炎药可以抑制环氧合酶的活性,从不同途径达到抑制肿瘤细胞的生长、诱导凋亡,抑制血管形成、降低肿瘤的侵袭力和转移性.肝癌是世界常见的恶性肿瘤之一,预后较差,形成机制尚未清楚,其预防和治疗水平有限.因此找到一种新的抗癌药物并研究其抗肝癌的作用机制,在肝癌的预防和治疗中有重要意义.本文对COX抑制剂与肝癌形成和肝癌的预防和治疗中进展作一综述. It was reported that the cyclooxygenase-2 (COX-2) and its products were over-expressed in many malignant tumors. Non-steroidal antiinflammatory drugs (NSAIDs) can inhibit COX activity, and also can reduce proliferation, enhance apoptosis, decrease angiogenesis and invasiveness of tumor cells. Hepatoma is one of common malignancies worldwide, and its prognosis is still extremely poor and the cellular mechanisms contributing to hepatic carcinogenesis are relatively unknown. Therefore, the prevention and treatment of liver cancer are limited. At present, it is important to find new drugs and investigate their action mechanisms. This article provides a brief review on the research progress of COX inhibitor in the prevention and treatment of hepatoma.
出处 《世界华人消化杂志》 CAS 北大核心 2009年第2期158-163,共6页 World Chinese Journal of Digestology
基金 黑龙江省教育厅2007年科学技术研究项目 No.11521184~~
关键词 环氧合酶 抑制剂 肝癌 非甾体类抗炎药 肿瘤 Cyclooxygenase Inhibitor Hepatoma Non-steroidal anti-inflammatory drugs Cancer
  • 相关文献

参考文献3

二级参考文献66

  • 1Dong-ShengHuang Ke-ZhenShen Jian-FengWei Thng-BoLiang Shu-SenZheng Hai-YangXie.Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2[J].World Journal of Gastroenterology,2005,11(2):204-207. 被引量:31
  • 2[1]Chandrasekharan NV,Dai H,Roos KL,Evanson NK,Tomsik J,Elton TS,Simmons DL.COX-3,a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs:cloning,structure,and expression.Proc Natl Acad Sci USA 2002; 99:13926-13931
  • 3[2]Zhang F,Warskulat U,Wettstein M,Schreiber R,Henninger HP,Decker K,Haussinger D.Hyperosmolarity stimulates prostaglandin synthesis and cyclooxygenase-2 expression in activated rat liver macrophages.Biochem J 1995; 312(Pt 1):135-143
  • 4[3]Feng L,Xia Y,Yoshimura T,Wilson CB.Modulation of neutrophil influx in glomerulonephritis in the rat with anti-macrophage inflammatory protein-2 (MIP-2) antibody.J Clin Invest 1995; 95:1009-1017
  • 5[4]Hussain T,Gupta S,Mukhtar H.Cyclooxygenase-2 and prostate carcinogenesis.Cancer Lett 2003; 191:125-135
  • 6[5]Peng JP,Su CY,Chang HC,Chai CY,Hung WC.Overexpression of cyclo-oxygenase-2 in squamous cell carcinoma of the hypopharynx.Hum Patho1 2002; 33:100-104
  • 7[6]Sheng H,Shao J,Morrow JD,Beauchamp RD,DuBois RN.Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.Cancer Res 1998; 58:362-366
  • 8[7]Vogiagis D,Brown W,Glare EM,O'Brien PE.Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels.Carcinogenesis 2001; 22:869-874
  • 9[8]Leng J,Han C,Demetris AJ,Michalopoulos GK,Wu T.Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation:evidence for Akt inhibition in celecoxib-induced apoptosis.Hepatology 2003; 38:756-768
  • 10[9]Kinoshita T,Takahashi Y,Sakashita T,Inoue H,Tanabe T,Yoshimoto T.Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells.Biochem Biophys Acta 1999; 1438:120-130

共引文献63

同被引文献13

  • 1Qin N,Zhang SP,Reitz TL. Cloning,expression and functional characterization of human cyclooxygenase-1 splicing variants:evidence for intron 1 retention[J].Journal of Pharmacology and Experimental Therapeutics,2005,(03):1298-1305.
  • 2Zhang A,Maner S,Betz R. Genetic alterations in cervical carcinomas:frequent low level amplifications of oncogenes are associated with human papillomavirus infection[J].International Journal of Cancer,2002,(05):427-433.
  • 3An HJ,Kim KR,Kim IS. Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma:a population based study[J].Modern Pathology,2005,(04):528-534.
  • 4Dubé C,Rostom A,Lewin G. The use of as pirin for primary prevention of colorectal cancer:a systematic review prepared for the U.S[J].Preventive Services Task Force[J].Annals of Internal Medicine,2007,(05):365-375.
  • 5Lang S,Picu A,Hofmann T. COX-inhibitors relieve the immunosuppressive effect of tumor cells and improve functions of immune effectors[J].International Journal of Immunopathology and Pharmacology,2006,(02):409-419.
  • 6Sorokin A. Cyclooxygenase-2:potential role inregulati on of drug efflux and multidrug resistance phenotype:New insight into COX-2 b iology and inhibition[J].Current Pharmaceutical Design,2004,(06):647-657.doi:10.2174/1381612043453117.
  • 7邹余粮,肖景华,裴美丽,苟文丽,张娟娟,张鹏花.阿司匹林联用PT化疗抑制人宫颈癌细胞株HeLa增殖的研究[J].现代妇产科进展,2009,18(8):599-601. 被引量:2
  • 8杨建林,韩钰,周永芹.阿司匹林促进宫颈癌HeLa细胞凋亡[J].基础医学与临床,2010,30(1):91-92. 被引量:2
  • 9Qi WANG,Wei-ying ZHANG,Li-hong YE,Xiao-dong ZHANG.A mutant of HBx (HBxΔ127) promotes hepatoma cell growth via sterol regulatory element binding protein 1c involving 5-lipoxygenase[J].Acta Pharmacologica Sinica,2010,31(3):367-374. 被引量:8
  • 10Jingwei Ma,Tucheng Sunt,Sujin Park,Guanxin Shen,Junwei Liu.The role of hepatitis B virus X protein is related to its differential intracellular localization[J].Acta Biochimica et Biophysica Sinica,2011,43(8):583-588. 被引量:7

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部